This benefit
in lisdexamphetamine augmentation significantly improved
executive dysfunction and depressive symptoms in participants
with mild MDD, with similar rates of treatment emergent adverse
event rates and consistent with prior studies in adults with
attention-deficit/hyperactivity disorder.